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It is a little known fact that Gregor Mendel, remembered 
for  his  studies  of  trait  inheritance  in  pea  plants,  also 
experimented  with  breeding  mice  to  understand  coat 
color traits. Had it not been for the disapproval of Bishop 
Anton  Ernst  Schaffgotsch,  who  led  the  Augustinian 
monastery  where  Mendel  studied,  he  might  well  have 
been credited as the father of mouse genetics [1]. Instead, 
CC Little started generating inbred lines of mice half a 
century  later,  driven  by  a  desire  to  understand  cancer 
biology and recognizing the importance of reproducible 
genetic crosses [1]. From these beginnings more than 300 
strains of laboratory mice have been developed; each line 
has been faithfully replicated and cryo-preserved, making 
them a renewable genetic resource. Most are the result 
of the blending together of Mus musculus sub-species, 
including domesticus and musculus, with some contri-
bu  tion  of  castaneous  and  molossinus,  resulting  in  a 
distinc  tive genetic mosaic of these progenitors in each 
inbred line [2].
Today’s geneticists usually turn to one of these inbred 
mouse strains when attempting to model human disease 
because  mice  offer  advantages  that  few  species  can 
match.  Importantly,  the  mouse  genome  can  be  easily 
manipulated with greater speed, scale and sophistication 
than  that  of  other  mammals,  and  the  efforts  of  the 
International  Mouse  Genome  Sequencing  Consortium 
has resulted in a high quality reference genome sequence 
that is the envy of other model organism users [3]. The 
future  for  mouse  genetics  promises  to  be  even  more 
exciting now that high-throughput sequencing of mouse 
strain genomes has started, and efforts are under way to 
systematically disrupt every gene in the mouse genome 
and phenotype the resulting mutant animals [4]. Here, 
we outline the tools and technologies that have emerged 
for using mice to discover and characterize disease genes, 
and the resources that are being developed to accelerate 
these discoveries.
Sequencing mouse genomes
In  2002  the  International  Mouse  Genome  Sequencing 
Consortium released the first draft of the genome from 
C57BL/6J, an inbred strain of the laboratory mouse [3], 
and a finished genome was released in 2009 [5]. As one of 
the most globally used lines, C57BL/6J was a wise choice 
for the reference mouse strain, but it is by no means the 
only  strain  used  in  research.  Therefore,  subsequent 
efforts  were  initiated  to  generate  genomic  sequence  of 
other inbred strains. Firstly, four different strains of the 
laboratory mouse were included by Celera in a whole-
genomic  shotgun  sequencing  project:  A/J,  DBA/2J, 
129X1/SvJ  and  129S1/SvImJ  [6].  This  resulted  in  27.4 
million sequencing reads, giving a total of 5.3x coverage 
of the mouse genome. Secondly, more than 150,000 short 
insert  clones  were  sequenced  from  the  129S5SvEvBrd 
strain covering 4.7% of the reference genome [7]. Thirdly, 
Perlegen Sciences used hybridization to re-sequence 15 
inbred mouse strains [8]; this set included 11 classical 
strains and four strains derived from the wild. Unlike the 
other  resources,  Perlegen’s  approach  did  not  generate 
sequence reads, and their hybridization sequencing tech-
nology  queried  only  1.49  Gigabases  of  the  reference 
genome  (equivalent  to  about  58%  of  the  C57BL/6J 
sequence  that  is  non-repetitive).  Furthermore,  to 
generate  high  accuracy  calls,  high  stringency  cutoffs 
were used, resulting in a false negative rate estimated to 
be as high as 50% [2]. Therefore, available sequence data 
lacked the coverage and breadth of strains to make it a 
widely used resource.
The  first  non-reference  mouse  chromosomes  to  be 
sequenced  were  A/J  and  CAST/EiJ  chromosome  17, 
reveal  ing significant variation at the nucleotide level and 
also considerable structural differences [9]. Building on 
that work, we commenced the Mouse Genomes Project, 
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© 2011 BioMed Central Ltdwhich  has  sequenced  the  genomes  of  17  key  mouse 
strains using next-generation sequencing on the Illumina 
platform  (Box  1).  At  the  last  data  freeze  in  December 
2009 an average of 25x sequence coverage of each strain 
had been generated, and a deep catalog of variants [10]. 
These data provide a comprehensive insight into the 
genomes of the 17 strains, allowing immediate access 
to  background  genetic  information  for  most  mouse 
models of disease in addition to facilitating the analysis 
of  the  molecular  basis  of  complex  traits  with 
unparalleled resolution.
Genetic manipulation of mice in the post-genomic 
era
Technologies for modifying the mouse genome can be 
split  into  two  broad  classes:  those  for  gene-driven 
analyses and those for random mutagenesis.
The  collection  and  propagation  of  mice  harboring 
spon  taneous mutations with striking phenotypes, such as 
the obese mouse, served mouse geneticists well for most 
of the 20th century. When it became clear that the rate of 
random germline mutation can be significantly increased 
by exposure to radiation or to chemical mutagens such as 
N-ethyl-N-nitrosourea  (ENU)  [11],  large-scale  muta-
genesis programs followed, resulting in an explosion in 
the number of mutant lines. Phenotypic screens of these 
lines led to the identification of many hundreds of new 
mutations  and  candidate  disease  genes  [12,13].  One 
notable example of a successful forward genetic screen, 
reviewed  in  [14],  identified  89  ENU-induced  mutants 
that influence the immune system, of which at least 69 
have  now  been  characterized  at  the  molecular  level. 
However,  mapping  random  mutations  and  identifying 
the affected gene can be an arduous process, often taking 
years; therefore, causal mutations for only a fraction of 
mutant  lines  have  been  identified  thus  far.  Screening 
DNA from archived mutagenized lines for mutations in a 
specific gene of interest is a parallel ‘gene driven’ strategy 
that  has  proven  successful  [15,16].  With  the  advent  of 
new sequencing technologies it is now cost effective to 
sequence  mutagenized  mouse  exomes  in  their  entirety, 
enabling the rapid identification of candidate disease genes 
from  existing  resources  and  meaning  that  mutagenesis-
driven  approaches  may  return  as  a  powerful  tool  for 
studying  disease  genes.  Other  methods  of  random 
mutagenesis include retroviruses, transposons (reviewed 
in [17]), and ‘gene traps’ [18]. These DNA-based mutagens 
can be easily mapped using approaches such as splinker-
ette PCR [19] and are discussed in more detail below.
The genome of the mouse can also be manipulated by 
pronuclear  injection  of  DNA  into  oocytes  or  by 
modification  of  embryonic  stem  (ES)  cells,  which  can 
then  be  injected  into  blastocysts  to  make  chimeras, 
allowing modified alleles to be transmitted through the 
germline. Direct pronuclear injection results in random 
integration  of  the  injected  DNA  [20];  consequently, 
trans  gene  copy  numbers  and  integration  sites  differ 
between  lines,  potentially  resulting  in  very  different 
pheno  types. Large genomic fragments such as bacterial 
artificial  chromosomes  (BACs)  may  also  be  injected 
(reviewed in [21]); these have proven particularly useful 
in complementation studies or ‘rescue’ experiments for 
identifying  genes  contributing  to  a  genetically  mapped 
disease trait of interest [22]. By contrast, DNA introduced 
into  ES  cells  in  culture  can  undergo  site-specific, 
homology-directed recombination [23], thus enabling the 
generation of targeted gain- and loss-of-function alleles 
as well as the engineering of large-scale rearrangements 
of entire mouse chromosomes (Figure 1) [24,25]. Other 
recently developed techniques include transgenic small 
hairpin RNAs (shRNAs), which are often delivered by 
lentiviral  transgenesis  [26,27],  single-stranded  oligo-
nucleo  tides (ssODNs; reviewed in [28]), and zinc-finger 
nucleases (ZFNs) [29], which can be used to generate 
subtle  sequence-specific  genomic  modifications.  Here 
we  will  address  in  more  detail  a  few  of  these 
technologies,  focusing  on  recent  advances  uniquely 
available to mouse geneticists.
ES cell gene-targeting
ES cell technology has been a profound advance in mouse 
genetics  (detailed  in  [30]).  Historically,  the  majority  of 
manipulations  have  been  performed  in  ES  cells  derived 
from 129 sub-strains (Table 1). Recently, robust and highly 
germline-competent  ES  cells  derived  from  the  popular 
C57BL/6 strains have been developed, such as JM8 and C2 
(Table 1). To assist in tracking the contri  bution of these ES 
cells  to  chimerism,  and  to  identify  mice  that  have 
transmitted  their  genome  through  the  germline,  a 
dominant Agouti (yellow) coat color allele was engineered 
in JM8 cells [31]. This now enables the study of mutant 
Box 1: A genome for all reasons
The 17 strains being sequenced as part of the Mouse Genomes 
Project were carefully selected to support other major mouse 
genetics resources. Three 129 strains were chosen because they 
serve as the background for thousands of existing gene knock-
outs. The C57BL/6N strain is the origin of the highly germline-
competent JM8 ES cells that are being used in large-scale gene 
targeting programs [31]. Nine common lab strains were chosen 
because of their historical utility, and also because they include 
the progenitors of the heterogeneous stock and Collaborative 
Cross mice that are used in dissecting complex traits [88,89]. 
Finally, four wild-derived strains have been sequenced because 
they represent some of the founder sub-species of many inbred 
laboratory lines, and are also important models of cancer and 
infection resistance [2].
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without the need for generations of backcrossing.
Gene targeting in mouse ES cells can be achieved by 
homologous recombination, using replacement, insertion 
or  knock-in  vectors,  all  of  which  contain  a  region  of 
homology with the locus to be targeted. In replacement 
vectors, crucial exons (or entire genes) are replaced by a 
selection  cassette  to  generate  a  null  knockout  allele 
(Figure  1a).  Knock-in vectors  are  designed such  that  a 
trans  gene or reporter is transcriptionally regulated by the 
endogenous promoter of the locus (Figure 1b; reviewed 
in  [32]).  By  contrast,  insertion  vectors  rely  on  gene 
rearrange  ment by interfering with splicing to disrupt a 
target gene (Figure 1c). Significant resources are available 
for obtaining suitable genomic DNA for targeting vector 
construction,  including  genome-wide  end-sequenced 
BAC libraries for C57BL/6J-derived [33] and 129-derived 
strains [7]. Homology arms (the part of the vector that 
aligns with the genome to facilitate recombination) were 
typically  generated  by  restriction  digest  of  large  DNA 
fragments  or  by  PCR  amplification,  but  increasingly 
‘recombineering’ technologies are being used [34], which 
make it possible to engineer virtually any mutation into 
the mouse genome with base pair resolution. In addition, 
customized  targeting  vectors  can  be  generated  on  a 
contract basis by several companies.
Gene modification with conditions
Conditional gene modification is used to enable spatial 
and/or  temporal  control  over  the  modification  of  the 
gene of interest. To this end, site-specific recombinase 
(SSR)  systems  are  used,  including  Cre-LoxP,  Flp-FRT, 
φC31 integrase-attB/attP and most recently Dre-rox [35]. 
For  a  comprehensive  review  of  the  use  of  site-specific 
recombinases for manipulation of the mouse genome, see 
[36].  The  DNA  sequences  that  the  SSRs  recognize  are 
typically directional and can either flank the target DNA 
for  excision  from  the  genome  or  be  used  to  invert 
Figure 1. Gene targeting strategies used in mouse ES cells. Targeting is achieved by recombination (black crosses) between homology arms 
(red lines). (a) A knockout vector replaces an entire gene with a selection cassette containing drug resistance (DR), enabling the selection of 
successfully targeted ES cell clones. (b) A knock-in vector allows the expression of a transgene, such as LacZ or Cre, by the promoter (gray arrow) 
of the targeted gene. (c) Insertion vectors can interfere with splicing by disrupting a target gene by the introduction of an exon with an early 
termination codon or a 5’ splice acceptor site (SA). They typically target the genome with a single crossover event. (d) A conditional allele with 
directional DNA sequences (LoxP, green triangles) either side of a critical exon. Recombination between the sites will result in a null allele. (e) LoxP 
sites can also be targeted megabases apart, either side of a larger cluster of genes, enabling chromosome engineering. (f) Heterospecific Lox sites, 
such as LoxP and Lox511, are targeted by the site-specific recombinase Cre. Recombinase-mediated cassette exchange (RMCE) enables the efficient 
swapping of one targeted cassette containing incompatible target sites for another cassette flanked by an identical pair of sites. This enables the 
rapid generation of new alleles, such as introducing a point mutation in a critical exon.
van der Weyden et al. Genome Biology 2011, 12:224 
http://genomebiology.com/2011/12/6/224
Page 3 of 11seg  ments of DNA. SSRs can be used for the generation of 
single  gene  knockouts  or  rearrangements,  and  for 
chromo  some  engineering  on  a  megabase  scale 
(Figure 1d,e) [37,38].
SSRs can be expressed from endogenous promoters (as 
shown  in  Figure  1b)  and  in  a  tissue-  or  cell-specific 
manner.  This  is  particularly  useful  when  studying  the 
organ-specific function of genes that are widely expressed 
and essential for embryonic development. For example, a 
conditional allele of Sox9, a gene implicated in campo-
melic  dysplasia  in  humans,  is  necessary  to  study  its 
function in cartilage in mice because germline deletion of 
Sox9  results  in  perinatal  lethality  [39].  For  somatic 
mutagenesis,  inducible  gene-modification  systems  may 
be used. These systems allow temporal ‘inducible’ control 
of SSR expression. There are several inducible expression 
systems available, including tetracycline [40], LacZ [41], 
and the tamoxifen-inducible systems [42]. These systems 
have  been  invaluable  in  studying  genes  and  neural 
circuits  involved  in  learning  and  memory,  by  turning 
genes and cellular markers ‘on’ or ‘off’ during controlled 
time periods (reviewed in [43]), and in a range of other 
biological systems.
There  are  now  over  500  tissue-  or  cell-specific  Cre 
recombinase mice (some of which are inducible) docu-
mented  in  databases  such  as  Cre-Zoo  and  Cre-X-mice 
(Table  2)  [44].  However,  as  conditional  modification 
tech  nologies  become  increasingly  sophisticated,  the 
potential for non-specific effects, from mis-regulation of 
the  targeted  gene  to  incomplete  recombination  by  the 
SSR, must remain a consideration [45,46]. For example, a 
recent study highlighted the potential for protein expres-
sion from episomal products of Cre recombinase-excised 
genes, particularly when deletion occurs in cells that have 
a low population turnover [47].
Recombinase-mediated cassette exchange
Using  homologous  recombination  to  introduce  genetic 
material  into  a  desired  genetic  location  in  the  mouse 
genome is not always straightforward. The efficiency is 
often dependent on the nature of the genomic target site 
and on the design of the targeting vector. Therefore, the 
ability to efficiently introduce secondary modifications to 
already  successfully  targeted  cassettes  is  advantageous. 
Recombinase-mediated  cassette  exchange  (RMCE)  is  a 
process  in  which  site-specific  recombinases  exchange 
one gene cassette, flanked by a pair of incompatible target 
sites, for another cassette flanked by an identical pair of 
sites (Figure 1f) [48]. Apart from the naturally occurring 
heterotypic SSR sites (attB and attP for φC31), several 
variant sites have been developed for Cre and Flp, provid-
ing the required heterospecificity crucial for RMCE (for 
example,  LoxP/Lox511  and  FRT/FRT3;  see  [49]  for  a 
complete list). In RMCE, typically one cassette is present 
in the host genome, whereas the other cassette (and the 
recombinase)  is  introduced  into  the  host  ES  cell  by 
electroporation, chemical-mediated or adenoviral-mediated 
gene transfer [50]. Transient expression of the recom  bi-
nase  will  direct  integration  of  the  SSR  site-flanked 
cassette, which can then be selected by drug resistance. 
RMCE-based techniques are proving to be useful in the 
rapid production of custom allelic series [51]: they have 
recently  been  used  to  compare  the  impact  of  different 
tumor-associated mutations in p53 [52], and to study the 
effect of multiple enhancer elements on the expression of 
a targeted cassette [53].
Table 1. Commonly used ES cell lines for generating genetically modified mice
ES cell line  Genetic background  Comments  Reference
E14TG2a  129P2OlaHsd  Feeder-independent; suitable for injections into C57BL/6 blastocysts  [104]
AB2.2  129S7/SvEvBrd-Hprtb-m2  Feeder-dependent  [105]
J1  129SvJae  Feeder-dependent  [106]
Bruce4  C57BL/6J-Thy1.1  Have a tendency to aneuploidy  [107]
B6/Blu-1  C57BL/6N  Generated by Tim Ley (Washington University, St Louis, USA)  Personal  
      communication 
JM8.parental  C57BL/6N  76% GLT rate  [31]
JM8.F6  C57BL/6N  Feeder-dependent JM8 subline. Suitable for injections in BALB/c or C57BL/6J-Tyrc/c blastocysts  [31]
JM8.N4  C57BL/6N  Feeder-independent JM8 subline. Suitable for injections in BALB/c or C57BL/6J-Tyrc/c blastocysts  [31]
JM8A1.N3  C57BL/6N  JM8.F6-derived line with a repaired Agouti locus. Feeder independent  [31]
C2  C57BL/6NTac  Efficient GLT using a combination of ICR morula aggregation with outbred host embryos  [108]
R1  129X1/SvJ x 129S1 (hybrid)  Feeder-dependent  [109]
G4  129S6/SvEvTac x C57BL/  Feeder-dependent; typically used for tetraploid complementation assays  [75] 
  6Ncr F1 hybrid
Abbreviations: GLT, germ line transmission; ICR, Institute for Cancer Research.
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Resource  Web site  Description  Reference
Australian Phenomics Network http://www.australianphenomics. 
org.au
Provides resources and services for producing, screening and 
archiving mutant mice
Canadian Mouse Mutant Repository http://www.cmmr.ca/ Archived ES cells, sperm, ova, embryos, and DNA
Cancer Models Database http://cancermodels.nci.nih.gov A database of mouse lines that model the genesis, progression 
or clinical course of human cancers
Center for Animal Resources and 
Development
http://cardb.cc.kumamoto-u.ac.jp/
transgenic
A repository of over 1,300 mutant lines
Centre for Modeling Human Disease http://www.cmhd.ca/databases ENU mutagenesis and gene trap databases
Collaborative Cross http://mouse.ornl.gov/projects/
collabcross.html
A resource for the genetic analysis of complex traits [110]
Cre-X-mice http://nagy.mshri.on.ca A Cre-expressing transgenic mouse line database [44]
CreZoo http://bioit.fleming.gr/crezoo A Cre-expressing transgenic mouse line database
Ensembl http://www.ensembl.org A genome database for mouse and other eukaryotes [111]
European Conditional Mouse 
Mutagenesis Program
http://www.eucomm.org Aims to generate and distribute a collection of 13,000 mutated 
ES cell lines using conditional approaches
[112]
European Mouse Disease Clinic http://www.eumodic.org Aims to generate phenome data on 650 knockout mice 
generated by the EUCOMM project
[82]
European Mouse Mutant Archive http://www.emmanet.org A European repository with over 1,700 mutant strains [113]
European Mouse Phenotyping 
Resource for Standardized Screens 
(EMPReSS)
http://empress.har.mrc.ac.uk A primary screening platform with over 100 standard operating 
procedures validated on inbred strains
[81]
European Union Mouse Research 
for Public Health and Industrial 
Applications
http://www.eumorphia.org Novel approaches in phenotyping, mutagenesis and informatics 
to improve the characterization of mouse models
[114]
EuroPhenome http://www.europhenome.org A database to hold phenome data from EMPReSS [115]
Federation of International Mouse 
Resources
http://www.fimre.org Coordinates repositories and resource centers globally [116]
GenomeSpace http://www.genomespace.org A central workspace for genomics tools, including Galaxy, 
Integrative Genomics Viewer and UCSC Browser
Heterogeneous Stock Phenotyping 
Project
http://mus.well.ox.ac.uk/mouse/HS A searchable map of QTLs that contribute to variation in over 
100 complex traits, using Heterogeneous Stock mice
[88]
International Gene Trap Consortium http://www.genetrap.org Information on >380,000 gene-trapped ES cell lines [117]
International Knockout Mouse 
Consortium
http://www.komp.org/ikmc Aims to minimize overlap, share resources, and improve services 
among the three major knockout projects
[79]
Knockout Mouse Project http://www.knockoutmouse.org Aims to target 8,500 genes and make mice available to the 
community
[4]
MouseBook http://www.mousebook.org MRC Harwell’s mouse resources; includes a frozen embryo 
and sperm archive, an ENU screen and DNA archive, and 
standardized phenotyping procedures
[118]
Mouse Genome Database http://www.informatics.jax.org Provides integrated genetic, genomic, and biological data on 
laboratory mouse strains
[119]
Mouse Genomes Project http://www.sanger.ac.uk/resources Raw sequence data, SNPs and assemblies of 17 mouse genomes 
Mouse Phenome Project http://phenome.jax.org A collection of baseline phenotypic data on commonly used 
inbred mouse strains
[83]
Mouse Resources Portal http://www.sanger.ac.uk/mouseportal The Sanger Institute’s resources; includes available BACs, 
gene targeting vectors, ES cells and mutant mouse lines with 
associated phenotypic data
[10]
Mutant Mouse Regional Resource 
Centers
http://www.mmrrc.org A repository of mouse stocks and ES cell lines
North American Conditional Mouse 
Mutagenesis project
http://www.norcomm.org Aims to target >2,000 genes that have not been previously 
targeted or trapped
[4]
PB Mutagenesis Information Center http://www.idmshanghai.cn/PBmice  A database for storing, retrieving and displaying information 
derived from PB transposon insertions
[120]
RIKEN Bioresource Center http://www.brc.riken.jp/lab/animal/en A Japanese repository of live and archived lines
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Unlike most of the methods described so far, which allow 
manipulation  of  the  genome  with  base  pair  precision, 
transposable elements provide the power to molecularly 
tag, and therefore rapidly map, random mutagenic events. 
The  application  of  transposons  to  the  field  of  mouse 
genetics has become possible only in the past decade. So 
far, four distinct DNA transposons have been shown to 
function in mice: Tol2, Minos, Sleeping Beauty (SB) and 
PiggyBac  (PB)  (reviewed  in  [17]),  with  the  latter  two 
being the most widely used. DNA transposons use a ‘cut-
and-paste’  transposition  mechanism.  When  both  the 
trans  posase enzyme and a transposon vector are present 
in  the  same  nucleus,  the  transposase  can  mediate 
excision  of  the  transposon  from  the  donor  site  and 
integration  into  another  target  site  in  the  host  cell 
genome. RNA-mediated transposition, driven by a ‘copy-
and-paste’  mechanism,  has  also  been  introduced  into 
mice for mutagenesis [54].
Transposons can be used for germline mutagenesis in 
mice  (reviewed  in  [55]).  However,  this  technique  is 
inefficient  for  genome-wide  forward  genetic  screens, 
owing to the low rate of transposition (one to three de 
novo insertions per gamete) and the tendency for local 
hopping exhibited by most of the transposons; though 
some  researchers  have  taken  advantage  of  this  obser-
vation to saturate smaller genomic regions [56,57]. So far, 
the most common use for transposons has been in the 
field  of  cancer  genetics  [17].  Retroviral  insertional 
mutagenesis  has  traditionally  been  used  to  study  the 
genetics of hematopoietic and mammary cancers (Box 2), 
but the study of other tumor types has been limited by 
viral tropism. Initial studies demonstrating the validity of 
transposon-mediated insertional mutagenesis (using SB) 
identified both known and novel cancer genes involved in 
sarcoma and lymphoma [58,59]. Since then, transposons 
have been engineered to produce gain-of-function muta-
tions in epithelial cells resulting in the development of a 
wide  variety  of  carcinomas  [60].  In  addition,  Cre-
inducible SB transposase alleles can restrict mutagenesis 
to  specific  tissues,  permitting  studies  into  colorectal 
cancer  and  hepatocellular  carcinoma  [61,62].  More 
recently,  PB  has  been  used  for  somatic  mutagenesis, 
representing another tool for cancer gene discovery in 
the mouse [63].
Transposons can also be used to generate transgenic 
mice by loading them with genetic cargo. SB, PB and Tol2 
are all efficient in delivering large transgenes, up to 70 kb 
in  size  [64].  PB  has  also  been  used  together  with  SSR 
technology to generate large-scale rearrangements of the 
mouse  genome,  including  duplications,  deletions,  and 
translocations [65]. Recently, transposons have been used 
to  deliver  the  reprogramming  factors  required  for 
generating induced pluripotent stem (iPS) cells [66,67].
Gene trap mutagenesis
Gene trapping in mouse ES cells is an efficient method 
for mutagenesis of the mammalian genome. Insertion of 
a  gene  trap  vector  can  disrupt  gene  function  and/or 
report gene expression, and because these vectors inte-
grate into the genome they provide a convenient tag that 
facilitates  the  identification  of  their  insertion  site.  A 
typical strategy involves electroporating into ES cells a 
vector containing a 5’ splice acceptor that splices to the 
upstream exon of the trapped gene, and thus the endoge-
nous promoter of the trapped gene is used to drive the 
expression of the reporter gene [18]. However, the vector 
can also be delivered by retroviral infection, or transposon-
mediated insertion and identification of the trap insertion 
sites  in  the  resultant  ES  cell  clones  performed  by 
splinkerette PCR (detailed in [68]).
Recent  developments  in  trapping  technology  involve 
the use of ‘conditional traps’, which enable the induced 
modification of trap alleles, in vitro or in vivo, using SSRs, 
Box 2: Exploiting viruses in mouse genetics
The first transgenic mice were generated by infecting embryos 
with viruses [97], and today viral vectors remain an integral 
part of the mouse genetics toolkit. Lentiviruses integrate 
their genome into the host’s DNA, making them an effective 
transgene delivery vector. The lentiviral genome, derived 
from immunodeficiency viruses, has been deconstructed 
and distributed across multiple plasmids to minimize the 
potential formation of replication-competent viruses [98]. 
A transgene of interest may be included in a plasmid containing 
a viral packaging signal. This is co-transfected into a cell line 
(typically human embryonic kidney HEK293T cells) with other 
plasmids expressing proteins required for viral production, 
such as envelope proteins. Viruses produced in this way can be 
introduced into oocytes for transgenesis (reviewed in [99]). In 
its simplest form, this method necessitates only a few weeks 
between target selection and phenotypic analysis, offering a 
distinct advantage over other approaches. To enable pooled 
loss-of-function screens to identify complex genetic interactions, 
lentiviral short hairpin RNA (shRNA) libraries targeting most 
mouse genes have been generated [27]. Some groups have 
recently used ultrasound-guided microinjections of lentiviruses 
to deliver genes to organs and tissues of early mammalian 
embryos in utero [100].
Slow transforming retroviruses have been widely used to 
generate mouse models of cancer [101]. They can re-infect the 
same cell, randomly inserting their genome into the host DNA 
multiple times, resulting in an accumulation of mutations. This 
process of progressive mutagenesis recapitulates the multi-
step progression of human tumorigenesis (reviewed in [102]). 
The development of next-generation sequencing technologies 
has dramatically enhanced the process of identifying retroviral 
insertion sites, and databases, such as the Retroviral Tagged 
Cancer Gene Database, have been developed to map insertion 
sites to the reference genome [103].
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functional cassettes [69]. Gene trapping strategies have 
also been successfully developed to screen for genes that 
have specific expression patterns (‘enhancer traps’ [70]) 
or are acting in specific biological pathways (‘induction 
trapping’ [71,72]). Another approach to direct gene trap-
ping toward genes in a specific pathway is to perform a 
phenotypic screen in ES cells. However, most insertions 
will cause heterozygous mutations (which will generate 
detectable phenotypes only for haploinsufficient genes). 
One strategy to overcome this has been to use ES cells 
that have a deficiency in the Bloom (Blm) DNA helicase. 
These  cells  show  high  levels  of  mitotic  recombination, 
which facilitates the generation of homozygosity in cell 
lines from colonies carrying heterozygous mutations [73].
‘ES cell-driven’ mouse production
Another advantage that the mouse has over other model 
organisms is in the rapid generation of mutant mice using 
ES cell-driven approaches. These enable the production 
of mice that are entirely, or almost entirely, derived from 
ES cells without the requirement for germline trans  mis-
sion. These approaches involve the injection of ES cells 
into  eight  cell  embryos  or  a  process  called  tetraploid 
comple  mentation  and  allow  the  generation  of  mutant 
mice in weeks rather than months [74,75]. By combining 
these  approaches  with  shRNA-mediated  knockdown, 
several groups have shown that it is possible to rapidly 
generate  knockdown  mice  for  the  analysis  of  somatic 
gene  function  [76,77].  Mice  somatically  overexpressing 
genes in an inducible and regulated way have also been 
developed using these approaches [78].
Mouse genetics on a grand scale
The success of the genome sequencing consortia over the 
past two decades established a model for further large-
scale, collaborative projects aimed at functionally charac-
terizing genomes (Table 2). Examples include the Inter-
national Knockout Mouse Consortium (IKMC), and its 
constituent regional projects, which collectively aim to 
generate mutant alleles for every protein-coding gene in 
the mouse genome and to make the resources available to 
the scientific community [4]. Researchers can now search 
the IKMC website and acquire, at minimal cost, mice or 
ES  cells  that  lack  a  gene  of  interest  [79],  thereby 
accelerating the path from a gene of interest to mutant 
mouse line. By May 2011, IKMC had over 16,000 ES cell 
lines with mutations in protein coding genes. Many of 
these alleles are ‘knockout first’ alleles, which are designed 
to introduce a LacZ expression marker into a target gene, 
and the allele can be tailored by using Cre and Flp to 
generate null and conditional alleles, respectively [80].
In parallel, a number of past and ongoing standardized 
phenotyping projects have documented traits in inbred 
strains  and  mutant  lines  for  phenotypes  relevant  to 
human disease, including the Mouse Phenome Project, 
the European Mouse Disease Clinic (EUMODIC) and the 
Mouse Genetics Project (MGP; based at the Wellcome 
Trust  Sanger  Institute);  see  also  Table  2  [81-84].  The 
results  from  many  screens  are  made  available  online, 
enabling  researchers  to  identify  potentially  interesting 
pheno  types for detailed analysis (Figure 2). For example, 
primary  MGP  analysis  of  mice  lacking  the  gene  Slx4 
identified a number of developmental and DNA instability 
phenotypes.  Detailed  secondary  analysis  revealed  the 
mouse  to  phenocopy  a  new  sub-type  of  the  human 
genetic illness, Fanconi anemia [85-87].
In an effort to identify quantitative trait loci (QTLs), 
large stocks of genetically heterogeneous (HS) mice have 
been  generated  [88,89].  Individual  mice  have  been 
phenotyped  and  genotyped  to  facilitate  high-precision 
QTL  mapping.  The  Collaborative  Cross  (CC)  is  a 
resource that is using a similar strategy by interbreeding 
eight strains of mice to generate around 300 new inbred 
lines [90], which, unlike HS mice, are being cryopreserved 
for  posterity.  It  is  estimated  that  the  CC  will  capture 
approxi  mately 90% of the genetic variability in laboratory 
mice and will allow the mapping of genetic networks that 
underlie  complex  diseases.  Moreover,  the  progenitor 
strains  of  the  CC  were  selected  for  sequencing  in  the 
Mouse Genomes Project (Box 1), which should allow the 
QTLs identified by phenotyping CC mice to be rapidly 
resolved into a list of candidate variants. When complete, 
the CC will mark a new era in the discovery of the mole-
cular basis of complex traits in the mouse. Meanwhile, 
large-scale phenotyping of the strains developed so far is 
well under way. Finally, EuTRACC is a project to generate 
ES cells that carry a targeted tandem affinity purification 
tag  (TAP-tag).  Initially  this  will  be  several  hundred 
transcription  factor  genes,  but  this  is  an  effort  that  is 
likely to extend genome-wide. This resource will facilitate 
mass spectrometry of native protein complexes to better 
understand the mouse ‘interactome’ [91].
Towards the future
Mouse genetics has a bright future. Genome-wide asso-
ciation  studies  have  identified  hundreds  of  alleles 
statistically associated with human disease, which now 
demand  detailed  functional  analysis.  Early  examples 
suggest the mouse will be the ideal model in moving from 
genetic  association  studies  to  understanding  molecular 
mechanisms leading to complex disease [92]. The abla-
tion of a large proportion of the coding mouse genome 
within the next 5 years, at least in ES cells, should rapidly 
accelerate these studies.
The  modular  design  of  modern  gene  targeting 
cassettes, together with SSRs and RMCE, makes for an 
incredibly flexible system of genetic engineering in mice. 
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scientific  disciplines  previously  dominated  by  work  in 
simpler  organisms.  For  example,  gene  targeting  com-
bined with channelrhodopsin, which allows the control 
of neural activation using light [93], allows the visuali-
zation, and fine manipulation, of precise neural circuits 
in  the  mammalian  brain  that  was  until  recently  only 
possible in Drosophila and C. elegans [94,95].
However, there are also challenges ahead. A significant 
number of regions across the mouse genome, typically 
those containing clusters of highly homologous, tightly 
arrayed  genes,  are  not  amenable  to  efficient  gene 
targeting. Moreover, the same loci are often difficult to 
sequence, with some lacking complete coverage even in 
the high quality reference genome [96]. Thus, as much as 
5  to  10%  of  the  functional  mouse  genome  may  fall 
through  the  cracks  of  the  present  large-scale  projects 
unless  new  technologies,  or  clever  combinations  of 
current  technologies,  are  developed  and  used  to 
investigate these genes. Nevertheless, the mouse is likely 
to  remain  the  non-human  vertebrate  with  the  most 
sequenced, and best studied, genome for the foreseeable 
future. Together, the advances described here will under-
pin  an  understanding  of  mouse  genetics  within  the 
current  decade  unthinkable  to  CC  Little  when  he  first 
began generating inbred lines over a century ago [1].
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